Evidence map›Paper›PMID 40614039›Full record

ArticleNeurology and therapy2025

Summary of Research: Blood Biomarker Dynamics in People with Relapsing Multiple Sclerosis Treated with Cladribine Tablets: Results of the 2-Year MAGNIFY-MS Study.

Heinz Wiendl, Frederik Barkhof, Xavier Montalban, Anat Achiron, Tobias Derfuss, Andrew Chan, Suzanne Hodgkinson, Alexandre Prat, Letizia Leocani, Klaus Schmierer and 8 more

Abstract readEditorial
PubMed Full text at PMC Publisher
In one paragraph

Article in Neurology and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Heinz WiendlDepartment of Neurology, Institute of Translational Neurology, University of Münster, Münster, Germany. heinz.wiendl@uniklinik-freiburg.de.
Frederik BarkhofDepartment of Radiology and Nuclear Medicine, Amsterdam UMC, Vrije Universiteit, Amsterdam, The Netherlands.
Xavier MontalbanDepartment of Neurology-Neuroimmunology, Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Hospital Universitario Valld'Hebron, Barcelona, Spain.
Anat AchironMultiple Sclerosis Center, Sheba Academic Medical Center, Ramat Gan, Israel.
Tobias DerfussDepartment of Neurology, University Hospital Basel, Basel, Switzerland.
Andrew ChanDepartment of Neurology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
Suzanne HodgkinsonIngham Institute for Applied Medical Research, University of New South Wales Medicine and Liverpool Hospital, Sydney, NSW, Australia.
Alexandre PratDepartment of Neurosciences, Université de Montréal, Montréal, QC, Canada.
Letizia LeocaniDepartment of Neurology, University Vita-Salute San Raffaele, Milan, Italy.
Klaus SchmiererThe Blizard Institute, Centre for Neuroscience, Surgery and Trauma, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK.
Finn SellebjergDanish MS Center, Department of Neurology, Copenhagen University Hospital - Rigshospitalet, Glostrup, Denmark.
Patrick VermerschUniv. Lille, Inserm U1172 LilNCog, CHU Lille, FHU Precise, Lille, France.
Hulin JinClinical Measurement Sciences, Merck Healthcare KGaA, Darmstadt, Germany.
Anita ChudeckaClinical Research Services, Cytel Inc., Geneva, Switzerland.
Andreas KloetgenClinical Measurement Sciences, Merck Healthcare KGaA, Darmstadt, Germany.
Dongdong LinClinical Measurement Sciences, EMD Serono Research & Development Institute, Inc., Billerica, MA, USA an affiliate of Merck KGaA, Darmstadt, Germany.
Lidia GardnerNeurology and Immunology Medical Unit, EMD Serono Research & Development Institute, Inc., Billerica, MA, USA, an affiliate of Merck KGaA, Darmstadt, Germany.
Nicola De StefanoDepartment of Medicine, Surgery and Neuroscience, University of Siena, Siena, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cladribine tablets (CladT) for relapsing multiple sclerosis help reset the immune system with short treatment courses over 2 years. This analysis of MAGNIFY-MS contrasted clinical outcomes with changes in immune cells, proteins and genes over 2 years in 270 participants. Most immune cells decreased 3 months after starting CladT. Gradual recovery was seen in naïve, regulatory, and transitional B cells starting at month (M)3 and M6. Gene activity related to immune response changes was also reported. Fewer cells producing pro-inflammatory signals and more cells producing anti-inflammatory signals were detected by M24. Immunoglobulin levels mostly remained normal, and a marker of neuroaxonal damage (serum neurofilament light chain) was decreased. Significant reductions in lesion count occurred from M2 onwards. Annualised relapse rate was 0.11 (95% confidence interval: 0.09, 0.15). Over 90% of participants were free of 6-month confirmed disability progression, around 87% had no confirmed progression on 9-hole peg test and timed 25-foot walk. No significant correlations were seen between clinical parameters and lymphocyte dynamics. The safety profile was consistent with previous studies. These findings provide evidence of CladT rebalancing the immune system towards a more homeostatic and less pathogenic state.

Indexed as

BiomarkersCladribine tabletsImmune reconstitution therapyImmunophenotypingMultiple sclerosisTranscriptomics

Identifiers

PMID40614039
PMCPMC12450126

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.